Navigation Links
Bradmer to present at Rodman & Renshaw Healthcare Conference
Date:11/3/2008

ioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab delivers tumor-killing radiation specifically to residual brain tumor cells after surgery, with minimal impact on normal brain tissue. During the course of development at Duke University, over US$60 million in research grants and related support has produced a series of Phase I and Phase II clinical trials on Neuradiab and other closely related technologies. Approximately 200 brain cancer patients, including over 160 with GBM, have been treated with the Neuradiab therapy regimen, and survival benefits have significantly exceeded historical controls in each completed trial. Neuradiab has been formerly referred to in literature as 131-I anti-tenascin monoclonal antibody 81c6.

Each year up to 30,000 new cases of GBM are diagnosed in the world's seven largest healthcare markets. GBM tumors typically have infiltrating edges that are very difficult to completely remove with surgery. The Neuradiab therapy is delivered directly into the surgical resection cavity in a separate procedure after the initial surgery. Neuradiab delivers a concentrated level of radiation specifically to the remaining cancer cells by targeting tenascin. Tenascin is a protein over-expressed in 99% of GBM cells but absent from normal brain cells.

About Bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administr
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
10. Bradmer announces new additions to management team
11. Bradmer announces 2008 first quarter operational and financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 On April 2, 2015, ... to Achieve Kylie Jenner Lips With Disastrous ... injured themselves while attempting an at-home lip augmentation ... is that creating an airlock around one’s mouth for ... plump and achieve Kylie Jenner’s now famous pout. (see: ...
(Date:4/21/2015)... April 21, 2015 “ ZeroWire ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... how ZeroWire is a security system and lifestyle management ... there were over 2 million burglaries in 2010. It ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Wireless Analytics, LLC , a pioneering ... the Boston Business Journal as the 25th fastest-growing private ... a recent event celebrating the 2015 Pacesetters, the ... companies in Massachusetts. , Wireless Analytics was ranked among ... the fastest revenue growth from 2011 through 2014. ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... - Health Professionals Calling for Further Guidance From Department ... plastic baby bottles has,been making headlines in North America, ... that 92%(1) of mums are not aware of the ... Us are phasing out,all baby bottles containing Bisphenol-A and ...
... A new report, funded and released by,Avalere Health, showed ... its,CY 2008 Part D Formulary Reference File. In response, ... Medicare offerings in 2008,resulting in significantly smaller Part D ... driven in part to remove hundreds of prescription,drugs that ...
... A large genetic study in mice has identified hundreds of ... DNA of more than 500 lymphomas to find the cancer ... mutations in total, which together implicate almost 350 regions in ... correspond to genes known to be involved in human cancers ...
... focuses on solving real-world problems ... in radiology, ... in radiology and medical image and information management solutions,today announced that its ... at the SIIM 2008,Annual Meeting in Seattle, WA, from May 15 to ...
... Life and Casualty,Company, a national life and health insurer, ... Alzheimer,s Association Rita Hayworth Gala for,their support of the ... "Bankers Life has organized Forget Me Not Days over ... 2003 to support both national and,local efforts," said Harry ...
... the use of pacemakers,implantable cardioverter-defibrillators (ICDs) and ... May 15 The American College,of Cardiology ... Heart Rhythm,Society (HRS) have jointly released updated ... for Device-Based Therapy of,Cardiac Rhythm Abnormalities are ...
Cached Medicine News:Health News:Bounty Poll Reveals British Mums in the Dark Over Bisphenol-A in Baby Bottles 2Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 2Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 3Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 4Health News:Connecting cancer genes 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 3Health News:Bankers Life and Casualty Company Named Corporate Honoree at Alzheimer's Association Chicago Rita Hayworth Gala 2Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 2Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 3Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 4
(Date:4/21/2015)... --  iRhythm Technologies, Inc. , a leading digital healthcare solutions ... today that Banner Health, one of the largest nonprofit ... offering iRhythm,s ZIO ® Service to patients in ... Banner Health, we are dedicated to strengthening our patient ... John Hensing , MD, Banner Health,s executive vice president ...
(Date:4/21/2015)... 21, 2015  Decision Diagnostics Corp. (OTC PINK: ... exclusive worldwide sales, service and regulatory processes agent ... Alternative Strip, specifically designed to work with the ... family of glucose testing meters, the most popular ... Johnson & Johnson/Lifescan has requested an unscheduled Case ...
(Date:4/21/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that 2015 first quarter financial results ... that day, the Company will hold a teleconference call ... discuss the results, followed by a question and answer ... and Chief Executive Officer of CryoLife, Inc. ...
Breaking Medicine Technology:Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 2Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 3Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 2Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 3CryoLife Announces Release Date and Teleconference Call Details for 2015 First Quarter Financial Results 2
... , , , , , ... PARIS and LAUSANNE, Switzerland ... innovation-driven global specialty,pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based ... of,prescription drugs that target unmet medical needs, announce the launch ...
... , THE WOODLANDS, Texas , Feb. 3 ... a biopharmaceutical company focused on discovering and developing breakthrough treatments for ... , Lexicon,s president and chief executive officer, will present at the ... on Monday, February 8, 2010 at 9:30 a.m., ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 2Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 3
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Anterior Chamber Needle, 27 g., 5 mm from bend to tip. Overall length 22 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Medicine Products: